Lexeo Therapeutics, Inc. SEC filings LXEO
Lexeo Therapeutics, Inc. has 361 filings in SEC EDGAR's recent list, going back to Feb 4, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (acquisition or sale of assets, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Oct 29, 2026 | — |
| S-8 | Employee stock plan registration | Mar 30, 2026 | — |
| 424B3 | Prospectus | Nov 26, 2025 | — |
| S-3 | Shelf registration | Nov 5, 2025 | — |
| S-8 | Employee stock plan registration | Nov 5, 2025 | — |
| 424B5 | Prospectus supplement | Oct 17, 2025 | — |
| FWP | Free writing prospectus | Oct 17, 2025 | — |
| 424B5 | Prospectus supplement | Oct 16, 2025 | — |
| FWP | Free writing prospectus | Oct 16, 2025 | — |
| 424B3 | Prospectus | Jul 1, 2025 | — |
| S-3/A | Filing | Jun 26, 2025 | — |
| S-3 | Shelf registration | Jun 13, 2025 | — |
| S-8 POS | Filing | Mar 24, 2025 | — |
| 424B5 | Prospectus supplement | Mar 24, 2025 | — |
| S-8 | Employee stock plan registration | Mar 24, 2025 | — |
| S-3 | Shelf registration | Dec 13, 2024 | — |
| POS AM | Filing | Dec 2, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 424B3 | Prospectus | Oct 30, 2024 | — |
| 424B3 | Prospectus | Oct 9, 2024 | — |
| 424B3 | Prospectus | Aug 12, 2024 | — |
| 424B3 | Prospectus | Jul 15, 2024 | — |
| 424B3 | Prospectus | Jul 8, 2024 | — |
| 424B3 | Prospectus | Jun 28, 2024 | — |
| 424B3 | Prospectus | May 9, 2024 | — |
| 424B3 | Prospectus | Apr 22, 2024 | — |
| 424B3 | Prospectus | Apr 22, 2024 | — |
| 424B3 | Prospectus | Apr 16, 2024 | — |
| 424B3 | Prospectus | Apr 12, 2024 | — |
| S-1 | Registration statement | Apr 9, 2024 | — |
| S-8 | Employee stock plan registration | Mar 11, 2024 | — |
| S-8 | Employee stock plan registration | Nov 7, 2023 | — |
| 424B4 | Prospectus | Nov 6, 2023 | — |
| FWP | Free writing prospectus | Nov 3, 2023 | — |
| S-1/A | Amended registration statement | Nov 1, 2023 | — |
| S-1/A | Amended registration statement | Oct 30, 2023 | — |
| S-1 | Registration statement | Sep 29, 2023 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LXEO (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1907108
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.